Nordic Nanovector ASA: Mandatory notification of trade - primary insider - correction

With reference to the previous notification of trade, the correct number of shares purchased today, 23 August 2019, by Malene Brondberg is not 1,722 shares, but 3,900 shares in Nordic Nanovector ASA (the "Company") at an average share price of NOK 25.38 per share. Following this transaction, Malene Brondberg owns 9,455 shares in the Company and holds 40,000 PSUs.

This information is subject to duty of disclosure pursuant to Section 4-2 and Section 5-2 of the Norwegian Securities Trading Act.

 

Tags:

About Us

About Nordic Nanovector Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information can be found at www.nordicnanovector.com. This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Subscribe